Sepracor, Inc. Release: Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor (Nasdaq: SEPR) today announced the presentation of Phase III study data for ALVESCO® (ciclesonide) HFA Inhalation Aerosol and Phase I data for a ciclesonide HFA MDI nasal aerosol formulation for the treatment of allergic rhinitis. These results were presented at the Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Seattle.